MannKind, GlaxoSmithKline, Myriad Genetics, and Alnylam Pharmaceuticals could all make waves in the biotech sector this morning.
Alexion's valuation doesn't seem unreasonable relative to the significant sales growth opportunities still in front of the company
The S&P 500 is at new records, and these stocks have been a big part of those gains. Find out more about these winning stocks here.
Valeant just made its first acquisition of the year. Let’s take a closer look at three companies -- Allergan, Actavis, and Zeltiq -- which could be threatened by the company’s inorganic growth.
Let's see what the numbers say about Abbott (ABT).
The Affordable Care Act is creating a variety of challenges and opportunities for health care companies. Medtronic is embracing a provision designed to reduce re-admissions by expanding into the home monitoring market.
Keep an eye on Amarin, Cubist, and Abaxis -- they could make big moves during today's trading.
While this product is unquestionably remarkable, are you considering the risks before buying Pharmacyclics at inflated prices?
With a share price gain of more than 1,000% over the trailing 12 months, this company and its CEO are at the forefront of cracking a tough-to-treat disease.
Even biotechnology stocks could use a facelift now and then. Alkermes CEO Richard Pops outlines the new path his company will be taking moving forward.